PanOptica Offers a “Do it Yourself” Treatment for Neovascular AMD

PanOptica – Paul Chaney, President & CEO for PanOptica, expands upon averting intravitreal injections with a topically, self-administered eye drop to treat Neovascular AMD. Striving to decrease the burden of injections and injection related risks, Paul shares the company’s unique discovery that led to their many successes.


Paul Chaney

Paul Chaney

Paul G. Chaney is Co-Founder, President & CEO of PanOptica Inc., a biopharma company developing PAN-90806, a novel topical anti-VEGF treatment for neovascular eye diseases.

View Full Profile